typical symptoms
[대역어] None
[용어속성] Symptom
[용어속성] Symptom
Quantity of IgG response to SARS-CoV-2 spike glycoprotein predicts pulmonary recovery from COVID-19
SARS-COV-2 스파이크 당 단백질에 대한 IgG 반응의 양은 COVID-19로부터 폐 회복을 예측한다.
Observational Study
[키워드] Abnormalities
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus-2
applied
association
Biomarker
Biomarkers
Care
Chain Reaction
Chest computed tomography
Clinical data
Clinical outcome
Computed tomography
Concentration
convalescent phase
coronavirus
coronavirus disease
coronavirus disease-2019
Coronavirus-2
correlated
COVID-19
COVID-19 patient
cut-off threshold
Diagnosis
elevated
evaluated
Follow-up
Follow-up visit
glycoprotein
IgG
IgG level
IgG response
immune activation
immunological
individual
initial
Intensive
Laboratory tests
marker
multicenter
Observational cohort study
participant
Patient
polymerase chain reaction
positive
positively correlated
predict
predicted
pulmonary CT
Pulmonary function
pulmonary injury
quantity
respiratory
RT-PCR
S glycoprotein
SARS-CoV-2
SARS-CoV-2 spike glycoprotein
serum
serum concentrations
serum IgG
Severe acute respiratory syndrome
severe acute respiratory syndrome Coronavirus
typical symptom
typical symptoms
Viral
viral infection
viral spike
[DOI] 10.1038/s41598-022-07489-6 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1038/s41598-022-07489-6 PMC 바로가기 [Article Type] Observational Study
Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model
단일 도메인 항체의 비강 전달은 동물 모델에서 SARS-CoV-2 감염의 증상을 개선합니다
Research Article
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
administration
alveolar
amplified
animal model
antibody
Behavior
block
blood stream
can not
cause
caused
Cell
cells
conditions
coronavirus
COVID-19
COVID-19 patients
cryo
Cryo-electron microscopy
cytokine
demonstrated
drug
drug candidates
electron microscopy
fusing
hamster
hamsters
host cell
host cell membrane
human lung organoids
immune reaction
IMPROVE
in vitro
infected cell
infected cells
infective
inhibited
lead
less
life-threatening
lung
Medical conditions
membrane
Microscopy
N-terminal domain
nasal
nebulizer
neutralize
neutralized
nose
occur
potency
Prevent
prevented
produced
progeny
receptor
Receptor binding domain
reducing
Reinfection
respiratory
risk
S protein
SARS-CoV-2
SARS-COV-2 infection
severe acute respiratory syndrome Coronavirus
severe pneumonia
Symptom
Symptoms
the disease
therapeutic drug
TMPRSS2
treat
treated
Treatment
typical symptom
typical symptoms
Vaccine
Viral
viral membrane
virus
weight loss
while
[DOI] 10.1371/journal.ppat.1009542 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.ppat.1009542 PMC 바로가기 [Article Type] Research Article
Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients
입원환자와 비입원환자의 급성 감염 후 6개월 후 증상
Article
Published on
Journal: Clinical microbiology and infection : the official
[Category] MERS, SARS, 진단, 치료기술,
Journal: Clinical microbiology and infection : the official
[Category] MERS, SARS, 진단, 치료기술,
[키워드] 95% CI
acute infection
acute respiratory syndrome
age
anti-SARS-CoV-2 IgG
bidirectional
chronic
Chronic COVID
coronavirus
coronavirus 2
COVID
COVID survivors
COVID-10
COVID-19
disease
disease onset
Early detection
evaluated
Factor
female
female gender
Follow-up
Gender
Hospitalized
ICU admission
identify
IgG antibodies
IgG antibody
increase in
independent risk factor
independent risk factors
individual
Inpatient
interview
investigated
IQR
Italy
Long
Long COVID
median
number of symptom
Occurrence
offered
onset of symptoms
Outpatient
outpatients
Patient
patients
Patients with post-COVID-19 syndrome
post-COVID syndrome
predictor
Prevalence
Prospective
Prospective Study
respiratory
SARS-CoV-2
SARS-CoV-2 antibodies
SARS-CoV-2 IgG
SARS-CoV-2 serology.
serological
serology
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
significantly
significantly higher
subgroup
Symptom
syndrome
the disease
the interview
titre
typical symptom
typical symptoms
with COVID-19
without symptom
[DOI] 10.1016/j.cmi.2021.05.033 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.cmi.2021.05.033 PMC 바로가기 [Article Type] Article
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
SPIKE-1: SARS-CoV-2 스파이크 단백질 개시 막 융합을 차단하여 COVID-19의 임상 진행을 줄이는 데 camostat의 사용을 평가하는 커뮤니티 환경에서의 무작위 2상/3상 시험
Letter
[키워드] 1:1
acute respiratory syndrome coronavirus
apyrexia
available data
baseline
best
Biomarkers
Blinding
camostat
clearance
Clinical improvement
clinical trial
Community
conducted
control arm
coronavirus
coronavirus 2
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 infection
COVID-19 symptom
COVID-19 symptoms
COVID-2019
Day
defined
Deterioration
determined by
diagnostics
disease
dissemination
duration of illness
Efficacy
element
eligibility criteria
Eligible patients
EudraCT
evaluate
Evidence
evidence of
Formal
four times daily
functional
Guidance
Health Organization
health protection
high risk
hospital
Hospital admission
Hospital admissions
Host
include
Infection
initial
Interactive Web Response System
interim analysis
Ireland
IWRS
Laboratory testing
maximum
membrane fusion
moderate
Mortality
multicentre
nasal
negative swab
number
objective
open
open label
Open-label
Ordinal Scale
outcome
outcome measure
overall mortality
oxygen
oxygen-free day
Oxygenation
participant
Patient
patient population
patients with SARS-CoV-2
performed
phase
PK data
Prevent
primary care
progression
protection
protocol
provided
Public
Public Health Agency
Public Health England
qPCR
questionnaire
randomisation
randomised
randomised controlled trial
receive
recruit
recruited
recruitment
reduce
reducing
refinement
requiring supplemental oxygen
Research
respiratory
risk
RT-PCR
Saliva
Sample size
Sample size calculations
SARS-CoV-2
SARS-COV-2 infection
secondary
Secondary objective
Secondary objectives
secondary outcome measures
serum antibody
Severe acute respiratory syndrome
severe acute respiratory syndrome coronavirus 2
severity
spike
status
supplemental oxygen
supplementary material
supplementary oxygen
supportive care
Swab
symptom severity
tablets
temperature
the patient
TMPRSS2
translational
Translational research
Treatment
treatment arm
Trial
trial protocol
Trial registration
typical symptom
typical symptoms
upper respiratory
Ventilation
ventilator
ventilator-free day
Ventilator-free days
Viral
Viral load
viral shedding
website
World Health Organization
[DOI] 10.1186/s13063-021-05461-9 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05461-9 PMC 바로가기 [Article Type] Letter
Prevalence and Predictors of Prolonged Cognitive and Psychological Symptoms Following COVID-19 in the United States
Neuroscience
[키워드] 95% CI
activity
adjusted
age
Analysis
Anxiety
average
coded
cognitive
Community
Community Dwellers
conducted
Contact
covariate
covariates
COVID-19
COVID-19 negative
COVID-19 positive subjects
COVID-19 symptoms
demographics
Depression
diagnosed
Diagnosis
disorder
dysfunction
eligible participant
Factor
fatigue
female
greater
group
Hispanic
identify
initial
Laboratory testing
logistic regression model
Long-hauler
male
measure
median
Metrics
multivariable logistic regression
NIH
no significant difference
not differ
occurred
participant
Participants
past medical history
platform
positive
Post-acute sequelae of SARS-CoV-2 infection
predict
Predictive
predictor
Prevalence
Primary outcome
Prolonged
proportions
psychological symptom
Quantitative
reported
Research
Result
Sex
significantly
significantly higher
stressors
subjects
subsequent
Symptom
the United State
typical symptoms
United State
[DOI] 10.3389/fnagi.2021.690383 PMC 바로가기 [Article Type] Neuroscience
[DOI] 10.3389/fnagi.2021.690383 PMC 바로가기 [Article Type] Neuroscience
COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study
입원 시 COVID-19 증상은 연령 및 성별에 따라 다릅니다. ISARIC 전향적 다국적 관찰 연구 결과
Case Reports
[키워드] abdominal pain
age
age and sex
Atypical
Case definition
children
Cohort
cohort of patient
Confusion
cough
country
COVID-19
COVID-19 case
COVID-19 symptom
Diagnosis
evaluate
Fever
hospital
Hospital admission
Hospitalized
hospitalized patient
hospitalized patients
International
ISARIC
laboratory-confirmed
Laboratory-confirmed COVID-19
less
Logistic regression
men
nationality
nausea
nausea and vomiting
observational study
Older
Older adults
Patient
presenting symptoms
prospective observational study
recruited
Regression
regression models
reported
reported symptoms
Result
SARS-CoV-2
Sex
Shortness of breath
significant difference
significant differences
supplementary material
Symptom
symptomatic patient
Symptoms
typical symptom
typical symptoms
vomiting
was performed
with COVID-19
women
[DOI] 10.1007/s15010-021-01599-5 PMC 바로가기 [Article Type] Case Reports
[DOI] 10.1007/s15010-021-01599-5 PMC 바로가기 [Article Type] Case Reports
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial
초기 SARS-CoV-2 Q-PCR 양성 고위험 개인(RES-Q-HR)의 회복기 혈장/카모스타트 메실레이트: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] accommodation
acts
Administered
administration
Adult patients
Adverse
adverse events
alcohol
Alcohol Abuse
ALT
anti-SARS-CoV-2 antibodies
anti-SARS-CoV-2 antibody
anticancer
Antiviral
antiviral therapy
appearance
approved
AST
blinded
Blinding
BMI
body weight
Bone marrow
Breastfeeding
CAD
camostat
Camostat mesylate
Capsule
Care
Caregivers
Cell
Child
chronic
Chronic kidney disease
chronic obstructive pulmonary disease
chronic obstructive pulmonary disease (COPD)
cirrhosis
CKD
clinical
clinical condition
Compliance
Concomitant
concurrent
conducted
control group
Controlled trial
convalescent plasma
COPD
Coronary artery
Coronary artery disease
cough
COVID-19
COVID-19 pneumonia
criteria
cumulative
defined
diabetes
Diabetes Mellitus
diagnosed
diagnosis of SARS-CoV-2
diarrhea
disease
Disease progression
disease stage
disorder
dissemination
double-blind
Duration
early disease
Early phase of SARS-CoV-2 infection
Efficacy
element
enrolled
Enrollment
enrolment
EudraCT
evaluate
evening
event
evidence of
Exanthema
excluded
exclusion criteria
fatigue
Fever
fibrosis
Germany
GFR
half-live
headache
high risk
higher risk
Hospitalization
Hospitalized
host cell
hypersensitivity
IgA deficiency
immunization
Inclusion
inclusion criteria
increased risk
independent
individual
Infection
infection with SARS-CoV-2
Influenza
influenza A
Informed consent
inhibitor
institution
intervention arm
intervention arms
Kidney disease
less
Life expectancy
likelihood
Liver cirrhosis
Local
local Ethics Committee
Mask
mesylate
moderate
mother
multicenter
nasal
nasal cannula
Neutralizing
number
objective
Obstructive
obstructive pulmonary disease
Older
Ordinal Scale
organ
outcome
outcomes
oxygen
oxygen demand
Pancreatitis
parallel group
participant
Participants
passive immunization
Patient
patients hospitalized
PCR
Placebo
plasma
Plasma transfusion
Pneumonia
positive
pregnant women
Presence
Prevent
prevent disease progression
primary endpoint
progression
protocol
pulmonary disease
pulmonary fibrosis
Q-PCR
randomization
Randomized
Randomized controlled trial
receive
recruitment
reduce
Regulatory
reported
risk factor
safety monitoring committee
Sample size
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 PCR
screening visit
Serine
serine protease TMPRSS2
Serious Adverse Event
Serious Adverse Events
severe COVID-19
Shortness of breath
SOC
sore throat
Stage
Standard
Standard of care
stratified
Stress
Study protocol
supplementary material
Symptom
symptom duration
Symptoms
tertiary care center
tested
the cell
titers
TMPRSS2
transfusion reaction
Treatment
treatment arm
Trial
Trial registration
Tumor
typical symptom
typical symptoms
ULN
virus
website
WHO
with COVID-19
women
working hypothesis
written Informed Consent
[DOI] 10.1186/s13063-021-05181-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05181-0 PMC 바로가기 [Article Type] Letter
SARS‐CoV‐2 rapid antigen test: Fast‐safe or dangerous? An analysis in the emergency department of an university hospital
SARS-CoV-2 신속 항원 검사: 빠른 안전 또는 위험한가요? 대학병원 응급실 분석
Research Article
[키워드] 95% confidence interval
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
AgPOCT
Analysis
Antigen
Asymptomatic
calculated
can be used
Chain Reaction
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID‐19
feasible
indicate
indicated
infectious
Inflammation
information
less
pandemic
Pandemics
Patient
patients
PCR
point of care
polymerase chain
polymerase chain reaction
positive
positive patients
Positive predictive value
Predictive value
question
respiratory
SARS Coronavirus
SARS‐CoV‐2
SARS‐CoV‐2 virus
sensitivity
severe acute respiratory syndrome Coronavirus
shown
specificity
Symptom
symptomatic and asymptomatic
symptomatic and asymptomatic patients
Symptoms
tested
the patient
threshold
typical symptoms
university hospital
without symptoms
[DOI] 10.1002/jmv.27033 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1002/jmv.27033 PMC 바로가기 [Article Type] Research Article
SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma
회복기 혈장으로 치료받은 2명의 신장 이식 및 2명의 혈액투석 환자에서 SARS-CoV-2 특이 체액성 및 세포성 면역
Case Reports
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
antibody
Antibody titers
antiviral drug
antiviral immunity
Antiviral treatment
Case report
cellular
cellular immunity
cellular response
Cellular responses
Chronic kidney disease
Clinical improvement
clinically
close monitoring
convalescent
convalescent plasma
coronavirus
COVID-19
Day
Deceased
described
discharged
ELISA
ELISPOT
ELISpot responses
enzyme
enzyme-linked immunosorbent
enzyme-linked immunosorbent assay
Hemodialysis
hospital
humoral
IgG
immune response
immune responses
Immunoglobulin
Immunoglobulin G
interferon
kidney
Kidney disease
kidney transplant
kidney transplant recipient
kidney transplantation.
Neutralization assay
neutralization titer
Neutralizing antibody titer
Patient
patients treated
Receptor-binding domain
Remdesivir
renal
respiratory
response
S1 subunit
SARS-CoV-2
SARS-CoV-2 spike protein
SARS-CoV-2-specific antibodies
SARS-CoV-2-specific antibody
severe acute respiratory syndrome Coronavirus
specific antibodies
Spike protein
the receptor-binding domain
the S1 subunit
the SARS-CoV-2
therapy
Transplant
Treatment
treatment regimen
typical symptom
typical symptoms
undetectable
Viral
Viral load
were infected
[DOI] 10.1002/jmv.26840 PMC 바로가기 [Article Type] Case Reports
[DOI] 10.1002/jmv.26840 PMC 바로가기 [Article Type] Case Reports